A vaccine adjuvant system and its application in COVID-19 and monkeypox virus vaccines

By wrapping ring dinucleotides based on the liposome delivery system of ionizable phospholipid IP9, ipSTING adjuvant was constructed, the problem of insufficient efficiency of existing adjuvant was solved, and the immune response of the new coronavirus and monkeypox virus vaccines was significantly improved, and the realization of the Efficient antibody and T cell immune response.

CN115381938BActive Publication Date: 2024-11-12FUJIAN NORMAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211124097.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-15
Publication Date
2024-11-12
Estimated Expiration
2042-09-15

AI Technical Summary

Technical Problem

Existing aluminum adjuvants are inefficient in inducing high-level antibody immune responses and stimulating antigen-specific T-cell immunity, especially for recombinant proteins that target SARS-CoV-2 and monkeypox viruses, and cyclic dinucleotides are used as PRRs. The poor transmembrane and poor stability of stimulators limit their biomedical applications.

Method used

Design a liposome delivery system based on ionizable phospholipid IP9 to wrap and deliver immunostimulator ring dinucleotides, build an ipSTING adjuvant system, efficiently wrap ring dinucleotides through hydrogen bond interaction, and in an acidic environment It can destroy the endosome membrane, promote cytoplasmic release, and significantly improve interferon secretion and CD86 activated protein expression.

Benefits of technology

It significantly improves the immunogenicity of recombinant protein antigens, induces high-titer antibodies and high-level T-cell immune responses, is better than commercial transfection reagents and aluminum adjuvants, and can quickly and efficiently improve the new coronavirus and monkeypox virus vaccines. Immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115381938B_ABST
    Figure CN115381938B_ABST
Patent Text Reader

Abstract

The present application discloses a vaccine adjuvant system, which comprises an ionizable phospholipid and a cyclic dinucleotide; the ionizable phospholipid molecule encapsulates the cyclic dinucleotide molecule. Delivery effect and vaccine adjuvant application experiments were conducted. With the help of the hydrogen bond interaction between the two, IP9 can efficiently encapsulate the cyclic dinucleotide through simple mixing to construct the adjuvant system ipSTING. Unlike traditional charged or uncharged phospholipids, IP9 has different molecular configurations at neutral and acidic pH, so it can respond to the acidic environment of the endosomal body and destroy the endosomal membrane, promoting the cytoplasmic release of cyclic dinucleotides.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to a vaccine adjuvant system and its application in COVID-19 and monkeypox virus vaccines, and belongs to the field of viral vaccines. Background Art

[0002] Following the COVID-19 pandemic, the epidemic caused by monkeypox virus was recently declared a "public health emergency of international concern" by the World Health Organization. Faced with the continuous emergence of new pathogens, the development of rapid and efficient vaccines has become an important direction and strategy for responding to the spread of various epidemics. Vaccine systems based on viral recombinant proteins as antigens are one of the mainstream technical routes for vaccine development. However, the recombinant proteins of SARS-CoV-2 and monkeypox virus generally have the problem of low immunogenicity. The aluminum adjuvants currently widely used are not efficient in inducing high-level antibody immune responses on the one hand, and have inherent deficiencies in stimulating antigen-specific T cell immunity on the other. Therefore, the development of an adjuvant system with universal and efficient adjuvant activity against pathogen protein antigens has important strategic significance and technical reserve value.

[0003] Pattern recognition receptors (PRRs), as the first line of defense of the body's immune system, play an important role in identifying and eliminating pathogens. Pattern recognition receptors can initiate the transcriptional response of innate immune genes, express cytokines such as interferon, promote humoral and cellular immune responses, and finally eliminate bacteria, viruses, and tumors by recognizing pathogen-associated molecular patterns and damage-associated molecular patterns. Based on this mechanism, the efficiency of the immune response of vaccines can be improved by injecting PRR stimulants. As one of the representatives of PRR stimulants, cyclic dinucleotides can efficiently induce the secretion of type I interferon, and thus show outstanding potential in the preparation of vaccine adjuvant systems. However, the poor transmembrane and poor stability of cyclic dinucleotides greatly hinder their further biomedical applications. Summary of the invention

[0004] To solve the above problems, the present invention designs a liposome delivery system based on ionizable phospholipid IP9 for loading and delivering immunostimulant cyclic dinucleotide. The present invention adopts the following technical solution:

[0005] A vaccine adjuvant system comprises ionizable phospholipids and cyclic dinucleotides; the ionizable phospholipid molecules encapsulate the cyclic dinucleotide molecules.

[0006] Optionally, the ionizable phospholipid has the following structural formula:

[0007]

[0008] Optionally, the method for preparing the ionizable phospholipid comprises the following steps:

[0009] Step 1) reacting 2-chloro-2-oxo-1,3,2-dioxaphospholane with n-nonanol to obtain a reaction product P3;

[0010] Step 2) reacting the reaction product P3 with dioctylamine to obtain the ionizable phospholipid.

[0011] Optionally, in step 1), 2-chloro-2-oxo-1,3,2-dioxaphospholane is added to a mixed solution of n-nonanol and triethylamine, and the mixture is reacted at room temperature for 10-20 hours;

[0012] Optionally, after the reaction of step 1) is completed, the triethylamine hydrochloride salt is filtered out, and the reaction product P3 is obtained by evaporation and concentration;

[0013] Optionally, in the step 2), the reaction product P3 and dioctylamine are dissolved in dimethyl sulfoxide and reacted at 65-75°C for 48-96 hours to prepare the ionizable phospholipid.

[0014] Optionally, after the reaction in step 2) is completed, dimethyl sulfoxide is evaporated to remove the dimethyl sulfoxide, and then gradient elution with dichloromethane and methanol is used to obtain the ionizable phospholipid.

[0015] The general structural formula of the cyclic dinucleotide is as follows:

[0016]

[0017] Where: B1 / B2=A, G, I;

[0018] X=H,OH,F;

[0019] Y=OH,SH.

[0020] Optionally, the cyclic dinucleotide has the following structural formula:

[0021]

[0022] Optionally, the mass ratio of ionizable phospholipids to cyclic dinucleotides in the vaccine adjuvant system is 1:0.05-0.5.

[0023] Optionally, the vaccine adjuvant system further comprises didecyl dimethyl ammonium bromide, cholesterol, dimyristoyl glycerol-polyethylene glycol 2000;

[0024] Optionally, the molar ratio of the ionizable phospholipid to didecyldimethylammonium bromide, cholesterol, and dimyristoylglycerol-polyethylene glycol 2000 is 1:0.25-4:0.25-4:0.003-0.02.

[0025] This application also proposes the application of the above vaccine adjuvant system in vaccines.

[0026] A novel coronavirus vaccine, comprising the above-mentioned vaccine adjuvant system and novel coronavirus antigen protein;

[0027] Optionally,

[0028] The concentration of the novel coronavirus antigen protein in the novel coronavirus vaccine is 0.05-0.5 mg / mL;

[0029] The concentration of cyclic dinucleotide in the new coronavirus vaccine is 0.05-0.5 mg / mL.

[0030] Optionally, the new coronavirus antigen is SARS-CoV-2RBD protein.

[0031] A monkeypox virus vaccine, wherein the novel coronavirus vaccine comprises the above-mentioned vaccine adjuvant system and monkeypox virus antigen protein;

[0032] Optionally,

[0033] The concentration of the monkeypox virus antigen protein in the monkeypox virus vaccine is 0.05-0.5 mg / mL;

[0034] The concentration of cyclic dinucleotide in the monkeypox virus vaccine is 0.05-0.5 mg / mL.

[0035] Optionally, the monkeypox virus antigen is monkeypox virus surface membrane protein A35R.

[0036] The beneficial effects of this application include:

[0037] The present invention selects cyclic dinucleotide CDG as a representative of the stimulant to construct an adjuvant system, and conducts delivery effect and vaccine adjuvant application experiments. With the help of the hydrogen bond interaction between the two, IP9 can efficiently encapsulate CDG through simple mixing to construct the adjuvant system ipSTING. Unlike traditional charged or uncharged phospholipids, IP9 has different molecular configurations at neutral and acidic pH, so it can respond to the acidic environment of the endosomal body and destroy the endosomal membrane, promoting the cytoplasmic release of CDG. Subsequent antigen presenting cell activation experiments have shown that ipSTING can significantly promote the entry of CDG into the cytoplasm, induce interferon secretion and the expression of CD86 activation protein. Moreover, the above activation characteristics are significantly higher than the activation levels brought about by commercial transfection reagents (Lipo) and perforin (PFO). In addition, further mouse immunization experiments have shown that the "ipSTING+recombinant protein antigen" vaccine system can significantly improve the immunogenicity of SARS-CoV-2RBD protein antigen and monkeypox virus A35R membrane protein antigen, induce high titer antigen-specific antibodies and high-level T cell immune responses, and are significantly better than control groups such as free CDG and commercial aluminum adjuvants. Based on this, the "ipSTING+recombinant protein antigen" system can be used as a rapid and efficient strategy for preparing viral vaccines such as the new coronavirus and monkeypox virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 Characterization of interferon secretion induced by ipSTING stimulating macrophages at the cell level (Lipo: commercial cationic liposomes (Lipofectmine 3000); PFO: perforin). ***: p<0.001;

[0039] Figure 2 Flow cytometry analysis of CD86 expression in RAW264.7 macrophages stimulated by ipSTING and the control group (CDG concentration 1 μg / mL); ***: p<0.001;

[0040] Figure 3 After the vaccine immunization was completed, the serum antibody titer of each group was measured based on ELISA. **: p<0.01, *: p<0.05;

[0041] Figure 4 After restimulation with the SARS-CoV-2 RBD protein antigen, mouse spleen CD69 + CD8 + Statistical graph of T cell population proportion. ***: p<0.001;

[0042] Figure 5 After the vaccine immunization was completed, the serum antibody titer of each group was measured based on ELISA. *: p < 0.05;

[0043] Figure 6 After restimulation with monkeypox virus A35R protein antigen, IFNγ in the spleen of mice + CD4 + Statistical graph of the proportion of T (interferon) cell population; (A) flow cytometry scatter plot, (B) statistical graph of proportion; **: p<0.01. DETAILED DESCRIPTION

[0044] The present application is described in detail below with reference to embodiments, but the present application is not limited to these embodiments.

[0045] The RBD in the example comes from Beijing Sino-Biological New Coronavirus Antigen RBD, item number 40592; A35R comes from Nanjing Okey Biotech Monkeypox Virus Antigen A35R, item number C1621. The aluminum adjuvant is from InvivoGen adjuvant 2%.

[0046] Unless otherwise specified, the raw materials in the examples of this application were purchased through commercial channels.

[0047] Example 1 Preparation of ipSTING delivery system

[0048] The synthesis route of ionizable phospholipid IP9 is as follows:

[0049]

[0050] P3 Synthesis

[0051] Take 0.87g of n-nonanol (P2) and 0.61g of triethylamine and add them to a 25mL round-bottom flask; take 5mL of anhydrous tetrahydrofuran (THF) into the flask, add a magnetic stirrer, and use a low-temperature reactor to cool to -15; take 0.85g (0.55mL) of 2-chloro-2-oxo-1,3,2-dioxaphospholane (P1) and dissolve it in a 10mL round-bottom flask containing 2mL of THF; slowly add P1 to the low-temperature n-nonanol (P2) solution through a syringe, after the addition is complete, remove the low-temperature reactor, and react at room temperature for 12h; after the reaction is completed, filter out the triethylamine hydrochloride salt, and concentrate the reaction product P3 by a rotary evaporator.

[0052] Synthesis of ionizable phospholipid IP9

[0053] 1.3 g of P3 and 1.15 g of dioctylamine (P4) were mixed and dissolved in 4 mL of DMSO, and reacted in an oil bath at 70°C for three days. After the reaction was completed, DMSO was removed by an oil pump rotary evaporator, and gradient elution was performed with a volume ratio of dichloromethane (DCM) to methanol (CH3OH) of 10:1 to 3:1 to separate and purify the target product, and finally IP9 was obtained by concentrating on a rotary evaporator and vacuum drying for 24 hours.

[0054] The cyclic dinucleotide CDG cyclic dinucleotide used in this application has the following structural formula:

[0055]

[0056] The compound is prepared based on the method of Example 1 in the inventor's patent CN 111592570 B.

[0057] ipSTING preparation

[0058] First, ethanol solutions of four compounds, IP9, DDAB (didecyl dimethyl ammonium bromide), cholesterol and DMG-PEG2000 (dimyristoyl glycerol-polyethylene glycol 2000), were mixed at a molar ratio of 60:30:40:0.4. Then, CDG with a CDG:IP9 mass ratio of 0.22 was added to the mixed solution, mixed evenly, and then phosphate buffer PBS was added to dilute to 2-6 times to complete the preparation of ipSTING. The dilution factor used in this example was 4 times.

[0059] Example 2 Evaluation of ipSTING antigen presenting cell activation

[0060] RAW-ISG was used to evaluate the ipSTING stimulation activity. After the cell culture was completed, 500,000 cells were plated in a 24-well plate and cultured overnight. The culture medium used for the RAW264.7 cell stimulation experiment was serum-free DMEM. ipSTING was loaded and used immediately. The stimulation concentration was CDG 1μg / mL and the volume per well was 500μL. After the incubation was completed, 70μL of the supernatant was taken, 10μL of luciferase substrate was added, and the chemiluminescence intensity was measured using an enzyme reader ( Figure 2 ). The cells at the bottom of the wells were then collected and stained with antibodies on ice (anti-CD86, Biolegend, 1 / 300 dilution). The cells were washed and analyzed on a BD LSRFortessa instrument, and the same method was used to compare cationic liposomes (Lipofectmine) and perforin (PFO). The results showed that compared to commercial cationic liposomes and perforin, ipSTING can effectively promote CDG transmembrane and activate antigen presenting cells by virtue of the structural change characteristics of IP lipids ( Figure 1 , Figure 2 ).

[0061] Example 3 Preparation and immunization of COVID-19 and monkeypox vaccines with ipSTING as adjuvant

[0062] ipSTING vaccine system: SARS-CoV-2 RBD protein or monkeypox virus A35R membrane protein (10 μg / unit; Beijing Sino-Bio Novel Coronavirus Antigen RBD, Catalog No. 40592; Nanjing Okey Biotech Monkeypox Virus Antigen A35R, Catalog No. C1621) and pre-prepared ipSTING (based on CDG content, containing 10 μg CDG / unit) were mixed and dissolved in PBS buffer. For the preparation process of aluminum adjuvant group vaccine, please refer to the adjuvant instructions ( adjuvant 2%). 6-8 week old female BALB / c mice were selected as vaccine immunization subjects, 3-5 mice per group. Each mouse was injected with each group of samples through subcutaneous immunization at the base of the tail, and the pH of the vaccine was controlled at 7.2-7.5. PBS was used as a blank control. The treatment groups were:

[0063] RBD treatment: SARS-CoV-2 RBD protein 10 μg / mouse;

[0064] RBD+Alum treatment: RBD protein 10 μg / mouse, aluminum adjuvant 300 μg / mouse;

[0065] RBD+CDG treatment: RBD protein 10 μg / mouse, CDG in Example 1 10 μg / mouse;

[0066] RBD+ipSTING treatment: RBD protein 10 μg / mouse; the ipSTING injection dose in Example 1 was CDG 10 μg / mouse;

[0067] A35R treatment: monkeypox virus A35R protein 10 μg / mouse.

[0068] A35R+Alum treatment: A35R protein 10 μg / mouse, aluminum adjuvant 300 μg / mouse.

[0069] A35R+CDG treatment: A35R protein 10 μg / mouse, CDG in Example 1 10 μg / mouse.

[0070] A35R+ipSTING treatment: A35R protein 10 μg / mouse; the ipSTING injection dose in Example 1 was CDG 10 μg / mouse.

[0071] The immunization procedure was performed three times in total, with injections every two weeks, and the mice were processed one week after all immunizations to collect spleen and serum samples.

[0072] Example 4 SARS-CoV-2 and monkeypox virus specific IgG antibody titers

[0073] The RBD protein and A35R were dissolved in 0.1M NaHCO3 (pH = 9.6) to prepare a 1 μg / mL solution, and added to a 96-well ELISA plate (Costar 3590) at a volume of 100 μL per well, and incubated at 4 for 12 hours. After washing with PBST solution (0.05% Tween in PBS solution), add 0.25% gelatin PBS solution to block at room temperature for 3 hours. After blocking, wash with PBS and PBST several times and control dry. The gradient diluted serum of each group in Example 3 was added to the well plate at a volume of 100 μL per well and incubated at 37 for 1.5 hours. Wash with PBS and PBST several times and control dry, add horseradish peroxidase (HRP) modified rabbit anti-mouse IgG antibody (1 / 2000 dilution), 100 μL, and incubate at 37 for 1 hour. After washing and drying again, add 200μL 3,3',5,5'-tetramethylbenzidine (TMB) to each well, keep it away from light for 4 minutes, and then add 2M sulfuric acid to stop the color development (50μL). Use a microplate reader to measure the absorbance value of each well (λ=450nm). The definition of the vaccine antibody titer in this article is the maximum dilution multiple at which the OD450 value is at least 0.1 higher than the blank group. The titer data show that the ipSTING adjuvant system can significantly increase the new crown RBD antigen ( Figure 3 ) and monkeypox A35R antigen ( Figure 5 )-specific IgG antibody levels were much higher than those in the control groups such as CDG and commercial aluminum adjuvant.

[0074] Example 5 Flow cytometry analysis of spleen cells stimulated by antigens after immunization of mice

[0075] The spleen tissue from mice immunized with a vaccine using RBD as an antigen was first ground and dispersed, and then the spleen cells were filtered using a 40μm cell strainer. The red blood cells in the spleen cells were lysed with red blood cell lysis buffer, and the cells were counted and added to a 96-well plate (1 million). Antigen stimulation concentration: SARS-CoV-2 RBD protein 25μg / mL, monkeypox virusA35R protein 25μg / mL. After incubation for 72 hours, the cells were centrifuged and stained on ice for 1 hour with αCD3 (17A2), αCD4 (RM4-4), αCD8α (53-6.7) and αCD69 (H1.2F3) antibodies. For intracellular cytokine staining, the cells were washed, treated with a membrane-penetrating reagent, and then incubated with intracellular cytokine (αIFN-γ and αTNF-ɑ) antibodies, and finally analyzed by flow cytometry. The flow cytometry results showed that the ipSTING adjuvant system can significantly increase the expression of the new crown RBD antigen ( Figure 4 ) and the intensity of cellular immune response to monkeypox A35R antigen ( Figure 6 ).

[0076] The above are only a few embodiments of the present application and do not constitute any form of limitation to the present application. Although the present application is disclosed as above with preferred embodiments, it is not intended to limit the present application. Any technician familiar with the profession, without departing from the scope of the technical solution of the present application, using the technical content disclosed above to make slight changes or modifications are equivalent to equivalent implementation cases and fall within the scope of the technical solution.

Claims

1. A vaccine adjuvant system, characterized in that: The vaccine adjuvant system comprises ionizable phospholipids and cyclic dinucleotides; the ionizable phospholipid molecules encapsulate the cyclic dinucleotide molecules; The ionizable phospholipid has the following structural formula: The cyclic dinucleotide has the following structural formula: The vaccine is a new coronavirus vaccine and / or a monkeypox virus vaccine.

2. The vaccine adjuvant system according to claim 1, characterized in that: The preparation method of the ionizable phospholipid comprises the following steps: Step 1) reacting 2-chloro-2-oxo-1,3,2-dioxaphospholane with n-nonanol to obtain a reaction product P3; Step 2) reacting the reaction product P3 with dioctylamine to obtain the ionizable phospholipid.

3. The vaccine adjuvant system according to claim 2, characterized in that: In the step 1), 2-chloro-2-oxo-1,3,2-dioxaphospholane is added to a mixed solution of n-nonanol and triethylamine, and the mixture is reacted at room temperature for 10-20 hours.

4. The vaccine adjuvant system according to claim 2, characterized in that: After the reaction in step 1) is completed, the triethylamine hydrochloride salt is filtered out and evaporated and concentrated to obtain the reaction product P3.

5. The vaccine adjuvant system according to claim 2, characterized in that: In the step 2), the reaction product P3 and dioctylamine are dissolved in dimethyl sulfoxide and reacted at 65-75° C. for 48-96 hours to prepare the ionizable phospholipid.

6. The vaccine adjuvant system according to claim 2, characterized in that: After the reaction in step 2) is completed, dimethyl sulfoxide is evaporated to remove the DMSO, and then gradient elution with dichloromethane and methanol is performed to obtain the ionizable phospholipid.

7. The vaccine adjuvant system according to claim 1, characterized in that: The mass ratio of ionizable phospholipids to cyclic dinucleotides in the vaccine adjuvant system is 1:0.05-0.

5.

8. The vaccine adjuvant system according to claim 1, characterized in that: The vaccine adjuvant system also includes didecyl dimethyl ammonium bromide, cholesterol, and dimyristoyl glycerol-polyethylene glycol 2000.

9. The vaccine adjuvant system according to claim 8, characterized in that: The molar ratio of the ionizable phospholipid to didecyl dimethyl ammonium bromide, cholesterol, and dimyristoyl glycerol-polyethylene glycol 2000 is 1:0.25-4:0.25-4:0.003-0.

02.

10. A novel coronavirus vaccine, characterized in that: The new coronavirus vaccine comprises the vaccine adjuvant system described in any one of claims 1 to 9 and a new coronavirus antigen protein.

11. The novel coronavirus vaccine according to claim 10, characterized in that The concentration of the novel coronavirus antigen protein in the novel coronavirus vaccine is 0.05-0.5 mg / mL; The concentration of cyclic dinucleotide in the new coronavirus vaccine is 0.05-0.5 mg / mL.

12. A monkeypox virus vaccine, characterized in that: The monkeypox virus vaccine comprises the vaccine adjuvant system according to any one of claims 1 to 9 and a monkeypox virus antigen protein.

13. The monkeypox virus vaccine according to claim 12, characterized in that The concentration of the monkeypox virus antigen protein in the monkeypox virus vaccine is 0.05-0.5 mg / mL; The concentration of cyclic dinucleotide in the monkeypox virus vaccine is 0.05-0.5 mg / mL.